INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR2m ago
SEC 13F2m ago
ROBINHOOD CHAIN2m ago
Public company

ALMRAlamar Biosciences, Inc.

CIK 0002104204

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 16
Max Insider Score30
Connections14with evidence

ALMR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
30
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$1.29M
49.0K sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • ← Insider ofevidence
    Qiming Corporate GP VI, Ltd.10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Qiming Managing Directors Fund VI, L.P.10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Qiming Venture Partners VI, L.P.10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Qiming GP VIII, LLC10% Owner · Oct 21, 2026
20
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL
$54K
1,947 sh
Oct 20, 2026
Oct 21, 2026
traded Oct 20, 2026
+1d
SEC FORM 4

Evidence

27
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$361K
13.7K sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

23
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$354K
12.4K sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

20
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$197K
7,415 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

27
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$301K
11.4K sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

23
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$565K
20.2K sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

17
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$9,527
335 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

20
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$99K
3,477 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

21
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$35K
1,320 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

26
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$2.02M
72.4K sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

17
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$5,326
200 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

20
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$83K
2,904 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

17
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$46K
1,730 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

23
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$472K
16.9K sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

20
QV
Qiming Corporate GP VI, Ltd.10% Owner
ALMRAlamar Biosciences, Inc.
Open-market sale
SELL$55K
2,072 sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

9
BL
Brottem John L.General Counsel
ALMRAlamar Biosciences, Inc.
Grant or award
A—
29.0K sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

9
BL
Brottem John L.General Counsel
ALMRAlamar Biosciences, Inc.
Grant or award
A—
85.0K sh
Sep 14, 2026Sep 16, 2026
traded Sep 14, 2026
+2dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
206.8K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
5,775 sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
5,775 sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
16.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
266.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
25.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

21
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
320.5K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

13
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
72.9K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
722.9K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
722.9K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

13
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
37.2K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
163.4K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

9
NN
Naclerio NicholasDirector
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
4.59M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
25.3K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
NN
Naclerio NicholasDirector
ALMRAlamar Biosciences, Inc.
Grant or award
A—
5,686 sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
24.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
24.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
20.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
20.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
27.7K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
1.03M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
176.2K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
300.9K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CS
Chen ShipingDirector, Chief Operating Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
300.9K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
341.2K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
1.02M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
366.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
880.8K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
LY
Luo YulingDirector, Chief Executive Officer
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
1.22M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Grant or award
A—
163.4K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
29.4K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
29.4K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
8,726 sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
WO
White Timothy OgdenPresident
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
8,726 sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CR
Chambers RebeccaDirector
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
140.6K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
CR
Chambers RebeccaDirector
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
140.6K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
MJ
McAnear Justin J.Chief Financial Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
37.2K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

9
MJ
McAnear Justin J.Chief Financial Officer
ALMRAlamar Biosciences, Inc.
Grant or award
A—
163.4K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

12
MJ
McAnear Justin J.Chief Financial Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
570.7K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
MJ
McAnear Justin J.Chief Financial Officer
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
570.7K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

17
NN
Naclerio NicholasDirector
ALMRAlamar Biosciences, Inc.
Derivative conversion
C—
922.2K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

12
NN
Naclerio NicholasDirector
ALMRAlamar Biosciences, Inc.
Other acquisition or disposition
J—
5.51M sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Qiming Venture Partners VIII Investments, LLC10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Qiming GP VIII-HC, LLC10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Qiming Venture Partners VIII-HC, L.P.10% Owner · Oct 21, 2026
  • ← Insider ofevidence
    Brottem John L.General Counsel · Sep 16, 2026
  • ← Insider ofevidence
    Luo YulingDirector, Chief Executive Officer · Apr 20, 2026
  • ← Insider ofevidence
    White Timothy OgdenPresident · Apr 20, 2026
  • ← Insider ofevidence
    Chambers RebeccaDirector · Apr 20, 2026
  • ← Insider ofevidence
    McAnear Justin J.Chief Financial Officer · Apr 20, 2026
  • ← Insider ofevidence
    Naclerio NicholasDirector · Apr 20, 2026
  • ← Insider ofevidence
    Chen ShipingDirector, Chief Operating Officer · Apr 20, 2026